129 related articles for article (PubMed ID: 29253572)
1. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin.
Kim YS; Jin HO; Hong SE; Song JY; Hwang CS; Park IC
Biochem Biophys Res Commun; 2018 Jan; 495(2):2004-2009. PubMed ID: 29253572
[TBL] [Abstract][Full Text] [Related]
2. RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells.
Yan Y; Luo K; Zhang H; Chai W
Hepatogastroenterology; 2013; 60(121):70-5. PubMed ID: 22975582
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Jin HO; Hong SE; Kim CS; Park JA; Kim JH; Kim JY; Kim B; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
Toxicol Appl Pharmacol; 2015 Aug; 287(1):17-25. PubMed ID: 25981168
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells.
Hong J; Nakano Y; Yokomakura A; Ishihara K; Kim S; Kang YS; Ohuchi K
J Pharmacol Exp Ther; 2006 Nov; 319(2):672-81. PubMed ID: 16895977
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression.
Kim YS; Jin HO; Seo SK; Woo SH; Choe TB; An S; Hong SI; Lee SJ; Lee KH; Park IC
Biochem Pharmacol; 2011 Aug; 82(3):216-26. PubMed ID: 21601561
[TBL] [Abstract][Full Text] [Related]
6. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
Zhang B; Liu ZM; Hao FG; Wang M
Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
[TBL] [Abstract][Full Text] [Related]
7. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro.
Zhang B; Zhang K; Liu Z; Hao F; Wang M; Li X; Yin Z; Liang H
Cell Physiol Biochem; 2014; 33(4):1162-75. PubMed ID: 24751980
[TBL] [Abstract][Full Text] [Related]
8. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
[TBL] [Abstract][Full Text] [Related]
9. IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin.
Ma X; Bai Y
Mol Med Rep; 2012 Dec; 6(6):1433-7. PubMed ID: 23027041
[TBL] [Abstract][Full Text] [Related]
10. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Okamoto K; Okamoto I; Okamoto W; Tanaka K; Takezawa K; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Cancer Res; 2010 Dec; 70(24):10402-10. PubMed ID: 21159653
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p.
Mu L; Yang F; Guo D; Li P; Zhang M
Bioengineered; 2020 Dec; 11(1):472-483. PubMed ID: 32250192
[TBL] [Abstract][Full Text] [Related]
12. Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin.
Hu W; Jin P; Liu W
Cell Physiol Biochem; 2016; 38(3):1199-208. PubMed ID: 26982182
[TBL] [Abstract][Full Text] [Related]
13. Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway.
Naik PP; Mukhopadhyay S; Praharaj PP; Bhol CS; Panigrahi DP; Mahapatra KK; Patra S; Saha S; Panda AK; Panda K; Paul S; Aich P; Patra SK; Bhutia SK
Life Sci; 2021 Jan; 264():118722. PubMed ID: 33160989
[TBL] [Abstract][Full Text] [Related]
14. Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway.
Xiu P; Xu Z; Liu F; Li Z; Li T; Zou F; Sun X; Li J
Dig Dis Sci; 2014 Aug; 59(8):1798-809. PubMed ID: 24671452
[TBL] [Abstract][Full Text] [Related]
15. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
Ma G; Cai H; Gao L; Wang M; Wang H
World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
[TBL] [Abstract][Full Text] [Related]
16. Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection.
Walker T; Nolte A; Steger V; Makowiecki C; Mustafi M; Friedel G; Schlensak C; Wendel HP
Eur J Cardiothorac Surg; 2013 Mar; 43(3):628-33; discussion 633-4. PubMed ID: 23152437
[TBL] [Abstract][Full Text] [Related]
17. Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo.
Zhang K; Li Y; Liu W; Gao X; Zhang K
Mol Med Rep; 2015 Jan; 11(1):639-44. PubMed ID: 25333812
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of vacuolar H+ ATPase enhances sensitivity to tamoxifen via up-regulation of CHOP in breast cancer cells.
Jin HO; Lee YH; Kim HA; Kim EK; Noh WC; Kim YS; Hwang CS; Kim JI; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
Biochem Biophys Res Commun; 2013 Aug; 437(3):463-8. PubMed ID: 23838288
[TBL] [Abstract][Full Text] [Related]
19. Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells.
Wang X; Yu Y; Zang L; Zhang P; Ma J; Chen D
Curr Pharm Biotechnol; 2020; 21(2):131-139. PubMed ID: 31433751
[TBL] [Abstract][Full Text] [Related]
20. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer.
Niu Z; Li X; Hu B; Li R; Wang L; Wu L; Wang X
Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):991-8. PubMed ID: 23099883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
